RAF1 anticorps

N° du produit ABIN7137997

Cet anticorps anti-RAF1 est un anticorps Lapin Polyclonal détectant RAF1 dans WB et ELISA. Adapté pour Rat.

Aperçu rapide pour RAF1 anticorps (ABIN7137997)

Antigène: RAF1 (V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1 (RAF1))

Reactivité: Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp RAF1 est non-conjugé

Application: Western Blotting (WB), ELISA

Détail du produit anti-RAF1 anticorps

Fonction: Raf1 Antibody

Réactivité croisée: Rat

Purification: Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide

Immunogène: Peptide sequence around aa. 641-645(T-S-P-R-L ) derived from Rat Raf-1.

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur RAF1

Antigène: RAF1 (V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1 (RAF1))

Autre désignation: Raf1

Sujet:

Background: A-Raf, B-Raf and c-Raf (Raf-1) are the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway (1). Activation of c-Raf is the best understood and involves phosphorylation at multiple activating sites including Ser338, Tyr341, Thr491, Ser494, Ser497 and Ser499 (2). p21-activated protein kinase (PAK) has been shown to phosphorylate c-Raf at Ser338 and the Src family phosphorylates Tyr341 to induce c-Raf activity (3,4). Ser338 of c-Raf corresponds to similar sites in A-Raf (Ser299) and B-Raf (Ser445), although this site is constitutively phosphorylated in B-Raf (5). Inhibitory 14-3-3 binding sites on c-Raf (Ser259 and Ser621) can be phosphorylated by Akt and AMPK, respectively (6,7). While A-Raf, B-Raf and c-Raf are similar in sequence and function, differential regulation has been observed (8). Of particular interest, B-Raf contains three consensus Akt phosphorylation sites (Ser364, Ser428 and Thr439) and lacks a site equivalent to Tyr341 of c-Raf (8,9). The B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma (10). Six residues of c-Raf (Ser29, Ser43, Ser289, Ser296, Ser301 and Ser642) become hyperphosphorylated in a manner consistent with c-Raf inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders c-Raf unresponsive to

Avruch, J. et al. (1994) Trends Biochem. Sci. 19, 279-283.
Chong, H. et al. (2001) EMBO J. 20, 3716-3727.
King, A.J. et al. (1998) Nature 396, 180-183.
Fabian, J.R. et al. (1993) Mol. Cell Biol. 13, 7170-7179.

Aliases: Raf1 antibody, Raf antibody, RAF proto-oncogene serine/threonine-protein kinase antibody, EC 2.7.11.1 antibody, Proto-oncogene c-RAF antibody, cRaf antibody, Raf-1 antibody

UniProt: P11345

Pathways: Signalisation MAPK, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, Neurotrophin Signaling Pathway, cAMP Metabolic Process, Stem Cell Maintenance, Hepatitis C, Autophagy, Signaling of Hepatocyte Growth Factor Receptor, VEGF Signaling, BCR Signaling